Albireo Pharma Inc ALBO Financial and Strategic SWOT Analysis Review [Updated: 15022017] Prices from USD $125

08:09 EDT 14 Mar 2017 | BioPortfolio Reports

Albireo Pharma Inc ALBO Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Albireo Pharma Inc Albireo, formerly Biodel Inc., is a specialty biopharmaceutical company that focuses on the development and commercialization of innovative bile acid modulators for the treatment of orphan pediatric liver diseases and other liver and gastrointestinal GI disorders and diseases where inappropriate flow of bile causes severe medical conditions for which there is high unmet need. The company's lead product candidate, A4250 is a novel, minimally absorbed, orally administered ileal sodium dependent bile acid transporter IBAT inhibitor. The product is in a Phase II clinical trial for progressive familial intrahepatic cholestasis PFIC, a rare, lifethreatening genetic disorder affecting young children and potentially other orphan pediatric liver diseases. Albireo is located in Boston, Massachusetts, the US.

Albireo Pharma Inc Key Recent Developments

Nov 29, 2016: Albireo Pharma appoints new chief regulatory officer
Aug 11, 2016: Biodel Reports Third Quarter Fiscal Year 2016 Financial Results
May 09, 2016: Biodel Reports Second Quarter Fiscal Year 2016 Financial Results
Feb 16, 2016: Biodel Reports First Quarter Fiscal Year 2016 Financial Results
Jan 29, 2016: Biodel Announces Restructuring Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Albireo Pharma Inc ALBO Financial and Strategic SWOT Analysis Review [Updated: 15022017] Prices from USD $125


More From BioPortfolio on "Albireo Pharma Inc ALBO Financial and Strategic SWOT Analysis Review [Updated: 15022017] Prices from USD $125"

Quick Search


Relevant Topic

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...